Strong government support, a talented workforce, and a thriving research environment drive life sciences excellence in Scotland - - BioPharm International

ADVERTISEMENT

Strong government support, a talented workforce, and a thriving research environment drive life sciences excellence in Scotland


BioPharm International


Scotland is also taking a leading role in funding early-stage ideas leading to the creation of new businesses or technology licensing. Companies such as Cyclacel ( http://www.cyclacel.com/), Axis Shield ( http://www.axis-shield.com/), Ardana ( http://www.ardana.co.uk/), and ProStrakan ( http://www.prostrakan.com/) that focus primarily on product development for the human healthcare market are prime examples of organizations that have received research and development funding from the government.

THE ROAD AHEAD

Scotland sees the future of life sciences as paved with great potential for discovery through international collaboration. Scotland is dedicated to communicating a global vision, in which a strong social, political, and academic infrastructure provides life sciences companies with a cohesive network of resources that are efficiently and effectively working together to achieve the goal of scientific discovery.

Scotland's life sciences community is a fine example of this vision, and is well positioned to remain a world leader in life sciences through the continued support of organizations such as SDI and ITI Life Sciences. These organizations are key to cultivating existing partnerships between academia and the global business community, while assisting business in seeking new research alliances and product development opportunities that will fuel the search for the latest innovations in science and technology. Those who share Scotland's vision stand to be part of a rich history and tradition in scientific research that has laid the groundwork for the next 100 years of scientific discovery.

LORNA B. JACK is president, Americas, for Scottish Development International, One Memorial Drive, Suite 1220, Cambridge, MA 02142, 617.621.3034, fax 617.621.3036,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here